tbuckley/cabot-search huggingface dataset:
Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial
Authors: Edo Richard, Eric P Moll van Charante, Marieke P Hoevenaar-Blom, Nicola Coley, Mariagnese Barbera, Abraham van der Groep, Yannick Meiller, Francesca Mangialasche, Cathrien B Beishuizen, Susan Jongstra, Tessa van Middelaar, Lennard L Van Wanrooij, Tiia Ngandu, Juliette Guillemont, Sandrine Andrieu, Carol Brayne, Miia Kivipelto, Hilkka Soininen, Willem A Van Gool
Journal: The Lancet Digital Health (2019)

BackgroundAlthough web-based interventions have been promoted for cardiovascular risk management over the past decade, there is limited evidence for effectiveness of these interventions in people older than 65 years. The healthy ageing through internet counselling in the elderly (HATICE) trial aimed to determine whether a coach-supported internet intervention for self-management can reduce cardiovascular risk in community-dwelling older people.MethodsThis prospective open-label, blinded endpoint clinical trial among people age 65 years or over at increased risk of cardiovascular disease randomly assigned participants in the Netherlands, Finland, and France to an interactive internet intervention stimulating coach-supported self-management or a control platform. Primary outcome was the difference from baseline to 18 months on a standardised composite score (Z score) of systolic blood pressure, LDL cholesterol, and body-mass index (BMI). Secondary outcomes included individual risk factors and cardiovascular endpoints. This trial is registered with the ISRCTN registry, 48151589, and is closed to accrual.FindingsAmong 2724 participants, complete primary outcome data were available for 2398 (88%). After 18 months, the primary outcome improved in the intervention group versus the control group (0·09 vs 0·04, respectively; mean difference −0·05, 95% CI −0·08 to −0·01; p=0·008). For individual components of the primary outcome, mean differences (intervention vs control) were systolic blood pressure −1·79 mm Hg versus −0·67 mm Hg (−1·12, −2·51 to 0·27); BMI −0·23 kg/m2 versus −0·08 kg/m2 (−0·15, −0·28 to −0·01); and LDL −0·12 mmol/L versus −0·07 mmol/L (−0·05, −0·11 to 0·01). Cardiovascular disease occurred in 30 (2·2%) of 1382 patients in the intervention versus 32 (2·4%) of 1333 patients in the control group (hazard ratio 0·86, 95% CI 0·52 to 1·43).InterpretationCoach-supported self-management of cardiovascular risk factors using an interactive internet intervention is feasible in an older population, and leads to a modest improvement of cardiovascular risk profile. When implemented on a large scale this could potentially reduce the burden of cardiovascular disease.FundingEuropean Commission Seventh Framework Programme.
Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes
Authors: Cirino Botta, Cristina Pérez Ruiz, Ibai Goicoechea, Noemi Puig, María Teresa Cedena, Lourdes Cordon, Aintzane Zabaleta, Leire Burgos, Catarina Maia, Sara Rodríguez, Idoia Rodriguez, Sarai Sarvide, Diego Alignani, Amaia Vilas-Zornoza, Erika Lorenzo-Vivas, Laura Rosinol Dachs, Albert Oriol, María Jesús Blanchard, Rafael Rios, Anna Sureda, Rafael Martínez, Jesús Martín, Joan Bargay, Javier De La Rubia, Marco Rossi, Pierosandro Tagliaferri, Pierfrancesco Tassone, Massimo Gentile, Juana Merino, Felipe Prosper, Alberto Orfao, Maria-Victoria Mateos, Juan-José Lahuerta, Joan Bladé, Jesús San-Miguel, Bruno Paiva
Journal: Blood (2019)
Analgesia in Midwifery
Authors: D. C. Devitt
Journal: BMJ (1948)

in my power I strove to awaken the Derby Division to a sense of the perpetual weakness of the B.M.A. inherent in the lack of integration between centre and periphery, the fruits of a long-standing distrust, by no means ill-founded on either side, between executive and rank and file.Dr. Charles Hill, who was then Assistant Secretary, attended the meeting, and with customary vigour did wash his hands in innocency, with the result that the motion was lost.That doctors will not attend Divisional meetings or take an interest in its affairs, and cannot therefore be depended uponhere for ever lies the gravamen of head office's complaint.But surely, Sir, if the mountain will not go to Mahomet, Mahomet should go to the mountain.At about the same time as the meeting above referred to I advocated the appointment of whole-time regional or district secretaries.Though this has since become official policy, we still await its implementation.It is a further .andlegitimate criticism that members of Council represent constituencies which are altogether too big.As many as three or four counties are combined together to
Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Authors: Craig A. Portell, Nolan A Wages, Brad S. Kahl, Lihua E Budde, Robert W. Chen, Jonathon B. Cohen, Gina Petroni, Michael E. Williams
Journal: Blood (2019)
Microneedle Sensor Monitors Antibiotics
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy
Authors: Shuangshuang Yang, Lijuan Chen, Jie Xu, Frank Xiao-Hu Fan, Sun Yan, Wen Wu, Yan Wang, Jin Wang, Shiwei Jin, Yuebo Zhou, Yuanfang Liu, Yan Zhuang, Wu Zhang, Jun-Min Li, Jian Hou, Jian-Yong Li, Zhu Chen, Jian-Qing Mi, Sai-Juan Chen
Journal: Blood (2019)
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
Authors: Stefania Oliva, Elisa Genuardi, Angelo Belotti, Pio Manlio Mirko Frascione, Monica Galli, Andrea Capra, Massimo Offidani, Federico Vozella, Renato Zambello, Daniel Auclair, Agostina Siniscalchi, Jennifer Yesil, Ombretta Annibali, Ilan M. Kirsch, Simona Caltagirone, Allison P. Jacob, Stelvio Ballanti, Angelo D. Palmas, Antonio Ledda, Paolo Corradini, Paola Omedé, Michele Cavo, Pellegrino Musto, Mario Boccadoro, Francesca Gay
Journal: Blood (2019)
A renaissance for polymaths
Authors: D Devakumar, NJ Russell, I Wolfe
Journal: Journal of the Royal Society of Medicine (2019)

In medicine, the generalist is the most common, and central, profession. Generalists are uniquely positioned to provide a comprehensive perspective and to coordinate care for the most complex and demanding problems. Their skill is in knowing enough about everything, while keeping the central purpose and humanity of care at the heart of their work. Their importance in an ever more complex world of medicine is clear.1 By contrast, generalists, or polymaths, in research and academia are rare. With increasing volumes and complexity of data and information, the sphere of specialism narrows, and the academic ivory tower grows higher and more remote from the needs and complexities of health research. The accepted narrative is that academic specialists define the cutting edge of research. Research funders generally favour supporting established world experts in their field, despite the narrowness of that field. This results in research echo chambers, where increasingly technologically sophisticated methods are applied to ever more refined questions, resulting in limited human benefit. The current model for addressing complex problems places specialists together in a multidisciplinary approach to combat siloed thinking. Boundaries are built up and then encouraged to be knocked down. But this is not always possible. We argue that research generalists or polymaths should sit at the centre of efforts to address complex problems.
ACTR-05. PROCARBAZINE AND CCNU CHEMOTHERAPY FOR RECURRENT GLIOBLASTOMA WITH MGMT PROMOTER METHYLATION
Authors: Yong Kil Hong, Seung Ho Yang
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND While procarbazine, CCNU (lomustine), and vincristine (PCV) has been an alternative chemotherapy option for malignant gliomas, it is worth investigating whether the combination of only procarbazine and CCNU is comparable because vincristine adds toxicity with uncertain benefit. The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation. METHODS Eight patients with recurrent GBM following concurrent chemoradiotherapy and temozolomide (TMZ) adjuvant therapy were enrolled in this trial; they received no other chemotherapeutic agents or target therapy. They received CCNU (75 mg/m2) on day 1 and procarbazine (60 mg/m2) through days 11 and 24 every 4 weeks. The median cycle of CCNU and procarbazine was 3.5 (range: 2–6). RESULTS One patient achieved stable disease. The median progression-free survival (PFS) with procarbazine and CCNU chemotherapy was eight weeks (range: 5–73), and the PFS rates were 25% and 12.5% at 16 and 30 weeks, respectively. The median overall survival (OS) from the initial diagnosis to death was 40 months, and the median OS from the administration of procarbazine and CCNU chemotherapy to death was 9.7 months (95% confidence interval: 6.7–12.7). Serious adverse events were found at six visits, and two cases were considered to be grade 3 toxicities. CONCLUSION The efficacy of procarbazine and CCNU chemotherapy is not satisfactory. This study suggests the need to develop other treatment strategies for recurrent and TMZ-refractory GBM
Varicose Veins in Pregnancy
Authors: H. Dodd
Journal: BMJ (1965)

fore in danger of being opened.The ex- posure is also difficult.After trying the above incision, I have now resorted to another.The skin is incised a few millimetres above the skin margin.The incision is therefore on the skin portion of the umbilicus.A thick white sheath is at once revealed.If this is incised horizontally with a deep cut the thick sheath gapes, and the insertion of an artery forceps will easily pick up the vein.The procedure is simple and takes only a few minutes.The incision heals well with a hardly noticeable scar.-I am, etc.,
Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma
Authors: Hiroshi Ito, Kosuke Watari, Tomohiro Shibata, Tomofumi Miyamoto, Yuichi Murakami, Yukiko Nakahara, Hiroto Izumi, Hiroaki Wakimoto, Michihiko Kuwano, Tatsuya Abe, Mayumi Ono
Journal: Cancer Research (2019)

The development of potent and selective therapeutic approaches to glioblastoma (GBM), one of the most aggressive primary brain tumors, requires identification of molecular pathways that critically regulate the survival and proliferation of GBM. Previous studies have reported that deregulated expression of N-myc downstream regulated gene 1 (NDRG1) affects tumor growth and clinical outcomes of patients with various types of cancer including glioma. Here, we show that high level expression of NDRG1 in tumors significantly correlated with better prognosis of patients with GBM. Loss of NDRG1 in GBM cells upregulated GSK3β levels and promoted cell proliferation, which was reversed by selective inhibitors of GSK3β. In contrast, NDRG1 overexpression suppressed growth of GBM cells by decreasing GSK3β levels via proteasomal degradation and by suppressing AKT and S6 cell growth signaling, as well as cell-cycle signaling pathways. Conversely, GSK3β phosphorylated serine and threonine sites in the C-terminal domain of NDRG1 and limited the protein stability of NDRG1. Furthermore, treatment with differentiation inducing factor-1, a small molecule derived from Dictyostelium discoideum, enhanced NDRG1 expression, decreased GSK3β expression, and exerted marked NDRG1-dependent antitumor effects in vitro and in vivo. Taken together, this study revealed a novel molecular mechanism by which NDRG1 inhibits GBM proliferation and progression. Our study thus identifies the NDRG1/GSK3β signaling pathway as a key growth regulatory program in GBM, and suggests enhancing NDRG1 expression in GBM as a potent strategy toward the development of anti-GBM therapeutics. SIGNIFICANCE: This study identifies NDRG1 as a potent and endogenous suppressor of glioblastoma cell growth, suggesting the clinical benefits of NDRG1-targeted therapeutics against glioblastoma.
Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening
Authors: Xi Qin, Rui Su, Lu Yang, Anthony K. N. Chan, Xiaolan Deng, Ying Qing, Lars Klemm, Markus Müschen, Chun-Wei David Chen, Jianjun Chen
Journal: Blood (2019)
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Authors: Joshua F Zeidner, Benjamin G. Vincent, Sonia Esparza, Anastasia Ivanova, Dominic T. Moore, Matthew C Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik W. Van Deventer, Laura Blanchard, William Churchwell, Cassiopeia Frank, Sean Gallagher, Melissa Matson, Ashley Reed, Nancy Vogler, Jonathan Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Leo Luznik, Jonathan S Serody, Ivana Gojo
Journal: Blood (2019)
Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells
Authors: Sudhakiranmayi Kuravi, Janice Cheng, Kishore Polireddy, Gabrielle Fangman, Roy A Jensen, Tara L. Lin, Siddhartha Ganguly, Joseph P. McGuirk, Ramesh Balusu
Journal: Blood (2019)
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF
Authors: Muthiah Vaduganathan, Brian L. Claggett, Akshay S. Desai, Stefan D. Anker, Sergio V. Perrone, Stefan Janssens, Davor Milicic, Juan L. Arango, Milton Packer, Victor C. Shi, Martin P. Lefkowitz, John J.V. McMurray, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2019)
Pregnancy in patients presenting with hyperprolactinaemia.
Authors: M O Thorner, C R Edwards, M Charlesworth, J E Dacie, P J Moult, L H Rees, A E Jones, G M Besser
Journal: BMJ (1979)

Ninety-two pregnancies occurred in 76 hyperprolactinaemic patients treated with bromocriptine. Half conceived within three months of attempted conception. There was no evidence of an increased rate of spontaneous abortion, fetal abnormality, or multiple pregnancy; the three twin pregnancies occurred in women who were additionally treated with clomiphene and human chorionic gonadotrophin. Thirty-one patients had radiological evidence of a pituitary tumour; 14 with major radiograph changes in the pituitary fossa or serum prolactin concentrations greater than 100 ng/ml received pituitary irradiation before conception. None of the latter showed evidence of enlargement of the tumour during pregnancy. In contrast two of the four patients with similar tumours but who were not irradiated developed visual field defects, one with gross destruction of the pituitary fossa. Prophylactic treatment to limit subsequent tumour expansion during pregnancy in patients with prolactinomas is indicated, and pituitary irradiation before conception appears to be a safe and effective method to achieve this goal.
Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP)
Authors: Jose Thiago de Souza Castro, Letícia Rittner, Simone Appenzeller, Gabriela G Yamaguti-Hayakawa, Marina Colella, Erich V De Paula, Joyce Maria Annichino- Bizzacchi, Fabiano Reis, Fernanda Andrade Orsi
Journal: Blood (2019)
Failure to Disclose Potential Conflict of Interest—Letter of Explanation
Authors: Samir M. Hanash, Ziding Feng, Ayumu Taguchi
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
COMP-03. QUANTITATIVE IMAGE FEATURE ANALYSIS IN DIFFUSE GLIOMA – A VALUABLE MR IMAGING BIOMARKER FOR PREOPERATIVE IDH MUTATION CLASSIFICATION
Authors: Eric Carver, James Snyder, Brent Griffith, Ning Wen
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Pre-operative differentiation of IDH mutant gliomas from similar appearing pathologies on imaging prior to definitive surgical diagnosis may aid treatment navigation, maximize the surgical approach, and provide diagnostic support for inoperable tumors. Quantitative image feature analysis offers a potential non-invasive method to identify diagnostic, prognostic, and predictive imaging biomarkers. We investigated the use of radiomic MR imaging features to classify tumors based on IDH mutation status. METHOD Pre-operative T1-weighted (T1W), T2-weighted (T2W), T1-contrast enhanced (T1CE), and fluid attenuated inversion recovery (FLAIR) MR brain images, along with patient IDH mutation status (mutant/wildtype) were obtained for 128 glioma patients from The Cancer Genome Atlas (TCGA). Enhancing tumor was delineated by GLISTRboost. GlistrBoost is a hybrid-discriminative model that segments tumors based on an expectation-maximization framework with a classification scheme and uses a probabilistic Bayesian strategy for segmentation refinement. MR studies for 78 glioma patients from six institutions were used for training and 50 glioma patients from a different institution were used for validation. Pre-processing included registration, resampling, and normalization. Cancer Imaging Phenomics Toolkit (CaPTK) extracted 938 radiomic image features per sequence for the enhancing tumor contour. Relevance of each individual feature was determined by the least absolute shrinkage and selection operator (LASSO). The ability of relevant radiomic image features to identify mutation status of IDH was assessed by logistic regression. RESULTS LASSO identified one highly informative radiomic imaging feature, the minimum of the mean absolute histogram deviation on T1 MR images, which was able to predict IDH mutation status with an accuracy of 0.74, precision of 1.0, and recall of 0.32. CONCLUSION Non-invasive prediction of IDH mutation status from pre-surgical MR images offers potential diagnostic, therapeutic, and prognostic benefits for glioma patients. Quantitative image feature analysis is a feasible method for identifying potential radiomic imaging features.
Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review
Authors: Maimoona Khan, Asma Waheed, Rida Ul Jannat, Arafat Ali Ali Farooqui, Muhammad Saad Farooqi, Ali Younas Khan, Madeeha Shafqat, Muhaddis Ejaz Ahmad, Muhammad Abdullah Yousaf, Tariq Iqtidar Sadiq Syed, Syed Maaz Abdullah, Sravanthi Kotapati, Irbaz Riaz, Faiz Anwer
Journal: Blood (2019)
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy
Authors: Merav Bar, Julia Ruark, Erin Mullane, Nancy Cleary, Ana Cordeiro, Evandro D. Bezerra, Jenna M. Voutsinas, Bronwen E. Shaw, Qian Vicky Wu, Kathryn E Flynn, Stephanie J. Lee, Cameron J. Turtle, David G. Maloney, Jesse Fann
Journal: Blood (2019)
In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles
Authors: Melanie Ricke-Hoch, Martijn F Hoes, Tobias J Pfeffer, Stella Schlothauer, Justus Nonhoff, Susanna Haidari, Nils Bomer, Michaela Scherr, Britta Stapel, Elisabeth Stelling, Yulia Kiyan, Christine Falk, Arash Haghikia, Ofer Binah, Zolt Arany, Thomas Thum, Johann Bauersachs, Peter van der Meer, Denise Hilfiker-Kleiner
Journal: Cardiovascular Research (2019)

Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease occurring in previously heart-healthy women. A common pathomechanism in PPCM involves the angiostatic 16 kDa-prolactin (16 kDa-PRL) fragment, which via NF-κB-mediated up-regulation of microRNA-(miR)-146a induces vascular damage and heart failure. We analyse whether the plasminogen activator inhibitor-1 (PAI-1) is involved in the pathophysiology of PPCM.In healthy age-matched postpartum women (PP-Ctrl, n = 53, left ventricular ejection fraction, LVEF > 55%), PAI-1 plasma levels were within the normal range (21 ± 10 ng/mL), but significantly elevated (64 ± 38 ng/mL, P < 0.01) in postpartum PPCM patients at baseline (BL, n = 64, mean LVEF: 23 ± 8%). At 6-month follow-up (n = 23), PAI-1 levels decreased (36 ± 14 ng/mL, P < 0.01 vs. BL) and LVEF (49 ± 11%) improved. Increased N-terminal pro-brain natriuretic peptide and Troponin T did not correlate with PAI-1. C-reactive protein, interleukin (IL)-6 and IL-1β did not differ between PPCM patients and PP-Ctrl. MiR-146a was 3.6-fold (P < 0.001) higher in BL-PPCM plasma compared with PP-Ctrl and correlated positively with PAI-1. In BL-PPCM serum, 16 kDa-PRL coprecipitated with PAI-1, which was associated with higher (P < 0.05) uPAR-mediated NF-κB activation in endothelial cells compared with PP-Ctrl serum. Cardiac biopsies and dermal fibroblasts from PPCM patients displayed higher PAI-1 mRNA levels (P < 0.05) than healthy controls. In PPCM mice (due to a cardiomyocyte-specific-knockout for STAT3, CKO), cardiac PAI-1 expression was higher than in postpartum wild-type controls, whereas a systemic PAI-1-knockout in CKO mice accelerated peripartum cardiac fibrosis, inflammation, heart failure, and mortality.In PPCM patients, circulating and cardiac PAI-1 expression are up-regulated. While circulating PAI-1 may add 16 kDa-PRL to induce vascular impairment via the uPAR/NF-κB/miR-146a pathway, experimental data suggest that cardiac PAI-1 expression seems to protect the PPCM heart from fibrosis. Thus, measuring circulating PAI-1 and miR-146a, together with an uPAR/NF-κB-activity assay could be developed into a specific diagnostic marker assay for PPCM, but unrestricted reduction of PAI-1 for therapy may not be advised.